PDF(Pubmed)
Abstract：
UNASSIGNED: Postinflammatory hyperpigmentation (PIH) is a common sequela of acne vulgaris. Topical treatment with hydroquinone is the standard treatment, but may be associated with complications. Cysteamine is a relatively safe depigmenting agent with an observed depigmenting effect. We designed this study to assess the efficacy of a cysteamine 5% cream in treating acne-induced PIH.
UNASSIGNED: Twenty-eight out of 32 participants finalized this investigator-blind, randomized, and controlled trial (registered in Iranian Registry of Clinical Trials [IRCTID: IRCT20140212016557N5]). We randomized the patients to apply either cysteamine 5% or hydroquinone 4%/ascorbic acid 3% (HC) cream. Postacne hyperpigmentation index (PAHPI) and melanin index were the assessment measures after four months of treatment. We evaluated the quality of life by the Dermatology Life Quality Index (DLQI) questionnaire.
UNASSIGNED: Both cysteamine and HC cream significantly decreased the PAHPI score and melanin index of acne-induced PIH patients (p<0.05). The decrease in PAHPI score and melanin index were not significantly different in treatment groups after four months (p>0.05). Quality of life ameliorated significantly only with cysteamine treatment. However, no significant change in quality of life was observed between groups.
UNASSIGNED: Limitations of our study include the relatively small sample size and absence of follow-up.
UNASSIGNED: Cysteamine cream is an effective treatment of post-acne PIH, with similar efficacy to the accepted treatment of PIH, i.e., hydroquinone cream.
UNASSIGNED: Twenty-eight out of 32 participants finalized this investigator-blind, randomized, and controlled trial (registered in Iranian Registry of Clinical Trials [IRCTID: IRCT20140212016557N5]). We randomized the patients to apply either cysteamine 5% or hydroquinone 4%/ascorbic acid 3% (HC) cream. Postacne hyperpigmentation index (PAHPI) and melanin index were the assessment measures after four months of treatment. We evaluated the quality of life by the Dermatology Life Quality Index (DLQI) questionnaire.
UNASSIGNED: Both cysteamine and HC cream significantly decreased the PAHPI score and melanin index of acne-induced PIH patients (p<0.05). The decrease in PAHPI score and melanin index were not significantly different in treatment groups after four months (p>0.05). Quality of life ameliorated significantly only with cysteamine treatment. However, no significant change in quality of life was observed between groups.
UNASSIGNED: Limitations of our study include the relatively small sample size and absence of follow-up.
UNASSIGNED: Cysteamine cream is an effective treatment of post-acne PIH, with similar efficacy to the accepted treatment of PIH, i.e., hydroquinone cream.
摘要：
■炎症后色素沉着过度（PIH）是寻常痤疮的常见后遗症。氢醌局部治疗是标准治疗，但可能与并发症有关。半胱胺是相对安全的脱色剂,具有观察到的脱色素效果。我们设计了这项研究来评估5％半胱胺乳膏治疗痤疮诱发的PIH的功效。
■32名参与者中有28人最终确定了这个研究盲，随机化，和对照试验（在伊朗临床试验注册中心注册[IRCT20140212016557N5]）。我们随机分配患者，分别使用5％半胱胺或4％氢醌/3％抗坏血酸（HC）乳膏。在治疗4个月后，波斯塔色素沉着过度指数（PAHPI）和黑色素指数是评估指标。我们通过皮肤病学生活质量指数（DLQI）问卷评估生活质量。
■半胱胺和HC乳膏均显着降低痤疮诱发的PIH患者的PAHPI评分和黑色素指数（p<0.05）。治疗组治疗4个月后PAHPI评分和黑色素指数下降无显著性差异(p>0.05)。仅使用半胱胺治疗，生活质量显着改善。然而,组间生活质量无显著变化.
■我们研究的局限性包括相对较小的样本量和缺乏随访。
■半胱胺乳膏是治疗痤疮后PIH的有效方法，与公认的PIH治疗相似的疗效，即，氢醌霜.
■32名参与者中有28人最终确定了这个研究盲，随机化，和对照试验（在伊朗临床试验注册中心注册[IRCT20140212016557N5]）。我们随机分配患者，分别使用5％半胱胺或4％氢醌/3％抗坏血酸（HC）乳膏。在治疗4个月后，波斯塔色素沉着过度指数（PAHPI）和黑色素指数是评估指标。我们通过皮肤病学生活质量指数（DLQI）问卷评估生活质量。
■半胱胺和HC乳膏均显着降低痤疮诱发的PIH患者的PAHPI评分和黑色素指数（p<0.05）。治疗组治疗4个月后PAHPI评分和黑色素指数下降无显著性差异(p>0.05)。仅使用半胱胺治疗，生活质量显着改善。然而,组间生活质量无显著变化.
■我们研究的局限性包括相对较小的样本量和缺乏随访。
■半胱胺乳膏是治疗痤疮后PIH的有效方法，与公认的PIH治疗相似的疗效，即，氢醌霜.
